ClOpidogrel - bienvenue sur le site de l'amiform

Can PLATelet Inhibition be Optimized to
Prevent Vascular Events: PLATO
~18,000 patients within 24 hours of
an index ACS (STEMI or NSTEMI)
AZD6140 90mg BID
ASA 75-100mg QD
Double-blind, double-dummy
Mean f/u ~12.5 months. Range 6-24
Clopidogrel 75mg QID
Primary Endpoint: Time to first occurrence of the
composite of death, MI or stroke.
Primary Safety Endpoint: Major bleeding
At least 2 inclusion criteria:
1. ST segment changes
biomarkers
2. At least 1:
- >60 yo
- Previous MI/CABG
- Known > 1 Vessel CAD
- AODM
- PVD
-Renal dysfunction
AODM, adult-onset diabetes mellitus; PVD, peripheral vascular disease.
Wallentin L, et al., for the PLATO study. A Comparison of AZD6140 and Clopidogrel in Patients With Acute
Coronary Syndrome. Washington, DC. US Food and Drug Administration. Available at: http://clinicaltrials.gov.